Login / Signup

Dasabuvir Inhibits Human Norovirus Infection in Human Intestinal Enteroids.

Tsuyoshi HayashiKosuke MurakamiJunki HiranoYoshiki FujiiYoko YamaokaHirofumi OhashiKoichi WatashiMary K EstesMasamichi Muramatsu
Published in: mSphere (2021)
Human noroviruses (HuNoVs) are acute viral gastroenteritis pathogens that affect all age groups, yet no approved vaccines and drugs to treat HuNoV infection are available. In this study, we screened an antiviral compound library to identify compound(s) showing anti-HuNoV activity using a human intestinal enteroid (HIE) culture system in which HuNoVs are able to replicate reproducibly. Dasabuvir (DSB), which has been developed as an anti-hepatitis C virus agent, was found to inhibit HuNoV infection in HIEs at micromolar concentrations. Dasabuvir also inhibited severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and human rotavirus A (RVA) infection in HIEs. To our knowledge, this is the first study to screen an antiviral compound library for HuNoV using HIEs, and we successfully identified dasabuvir as a novel anti-HuNoV inhibitor that warrants further investigation. IMPORTANCE Although there is an urgent need to develop effective antiviral therapy directed against HuNoV infection, compound screening to identify anti-HuNoV drug candidates has not been reported so far. Using a human HIE culture system, our compound screening successfully identified dasabuvir as a novel anti-HuNoV inhibitor. Dasabuvir's inhibitory effect was also demonstrated in the cases of SARS-CoV-2 and RVA infection, highlighting the usefulness of the HIE platform for screening antiviral agents against various viruses that target the intestines.
Keyphrases
  • hepatitis c virus
  • sars cov
  • endothelial cells
  • respiratory syndrome coronavirus
  • induced pluripotent stem cells
  • healthcare
  • high throughput
  • mesenchymal stem cells
  • hiv infected
  • hepatitis b virus
  • drug induced